FDA grants swift review to Lynparza in first-line prostate cancer
AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its […]
prostate cancer
Novartis’ Pluvicto gets first European approval in GB
Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products […]
FDA okays ProstatID software for detecting prostate cancer in MRI
Magnetic resonance imaging (MRI) technology specialist Bot Image has won FDA approval for its artificial intelligence-powered software ProstatID, used for the detection and diagnosis of […]
Bayer bags swift OK for Nubeqa in metastatic prostate cancer
Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from […]
Keytruda fluffs its lines in prostate, liver cancer trials
Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once […]
How Effective Is Chemotherapy for Colon, Lung, Breast, and Prostate Cancers?
How effective is chemotherapy for colon, lung, breast, and prostate cancers? “Over the last several decades…medicine has waged a major war against cancer, concentrating on […]
Merck strikes a $290M deal for novel prostate cancer drug
Merck is partnering with Orion on the clinical development and potential commercialization of a new drug for advanced prostate cancer. Though Merck already has a […]
Merck buys into Orion prostate cancer therapy in $290m deal
Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland’s Orion for ODM-208, a prostate cancer candidate […]
RhoVac pummelled as lead cancer vaccine fails study
Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate cancer vaccine […]
The work-from-home culture is slowing progress in the fight against prostate cancer
Studies have shown that men are less likely to use preventive healthcare services than women, and do not seek immediate treatment for many of their […]
Viagra-Type Drugs and Melanoma Skin Cancer
What is the role of erectile dysfunction drugs like Cialis and Levitra in the promotion and progression of prostate cancer and melanoma? Of the half-dozen […]
UK grants early access to Novartis’ prostate cancer radioligand
The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis’ Advanced Accelerator Applications (AAA) […]
Novartis gets first OK for radioligand Pluvicto in prostate cancer
Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval […]
Novartis targeted radiation therapy gets FDA nod for advanced prostate cancer
The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition […]
Merck trial of Keytruda, Lynparza combo in prostate cancer fails
Merck & Co’s two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously […]
Modest activity, tolerability issues sink lead Harpoon cancer drug prospect
Harpoon Therapeutics is discontinuing work on its lead drug in prostate cancer following disappointing data in an early-stage clinical trial. Though Harpoon has other drugs […]
Chasing rivals, Bayer files Nubeqa for new prostate cancer use
Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs […]
Mayo Clinic Tests Shark Cartilage Supplements for Cancer
Shark cartilage supplements carry risks, but so do many cancer treatments. The question is, do they work? When it comes to marketing unproven cancer treatments, […]
Bayer triples sales forecast for prostate cancer drug Nubeqa
Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, […]
Can Alcohol Cause Cancer?
If even light drinking can cause cancer, why don’t doctors warn their patients about it? As I discuss in my video Can Alcohol Cause Cancer?, […]
After a Scottish aye, NICE says no to Lynparza for prostate cancer
AstraZeneca’s PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, according to […]
Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer
Bayer’s Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand the eligible patient population for […]
Learn More Than 97% of Doctors About Lead-Time Bias
After reading this, you’ll know more than an estimated 97 percent of doctors about a critical concept called lead-time bias. While running for president of […]
Helix web tool guides prostate cancer genetic testing
A web-based digital tool called Helix could help clinicians identify patients with prostate cancer who would benefit from genetic testing and counselling, according to researchers […]
Why Are Mammogram Guidelines Conflicting?
When women are fully informed about the risks and benefits of mammograms, 70 percent may choose not to get screened. You may be in that 30 […]
PROpel study backs Lynparza combo in first-line prostate cancer
AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the […]
Memorial Sloan Kettering spinout gets first FDA clearance for AI to detect prostate cancer
Paige received clearance from the Food and Drug Administration for a clinical decision support tool to flag potential prostate cancer cases for radiologists to review.
FDA clears AI-powered prostate cancer detection software
Software that can help pathologists detect prostate cancer from slides of biopsies more effectively has been approved by the FDA. The software – called Paige […]
NICE changes its mind on J&J’s Erleada in prostate cancer
NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use […]
NICE second Zytiga rejection ‘shows need for flexible pricing models’
NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a treatment for men with newly diagnosed advanced […]
ViewPoints Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs
In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement […]
New Therapy for Aggressive Prostate Cancer Improves Survival
The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers.
New Therapy for Aggressive Prostate Cancer Improves Survival
The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers.
New Therapy for Aggressive Prostate Cancer Improves Survival
The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers.
Prostate Cancer Drug Development Summit
The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of […]
Bayer props up sagging radionuclide business with Noria acquisition
Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its […]
ASCO21: Novartis’ prostate cancer radiotherapy extends survival
Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment […]
Novartis radiopharmaceutical improves survival in key prostate cancer study
Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will […]
Tomato Sauce Put to the Test for Prostate Cancer
What happened when cancer patients were given three quarters of a cup of canned tomato sauce every day for three weeks? “Occasionally…positive things happen in […]
Lycopene Supplements Put to the Test
High doses of lycopene—the red pigment in tomatoes—were put to the test to see if it could prevent precancerous prostate lesions from turning into full-blown […]
NICE rejects J&J’s prostate cancer drug Erleada in initial guidance
NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The […]
Are Avocados Associated with Greater Risk or Reduced Risk of Cancer?
Avocado consumption can improve artery function, but what effect might guacamole have on cancer risk? In my last video about avocados, The Effects of Avocados […]
J&J decides against Erleada+Zytiga combination prostate cancer filing
Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it […]
ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment
In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the […]
Novartis’ radioligand therapy meets phase 3 prostate cancer trial target
Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. […]
NICE says no to AZ’s Lynparza for prostate cancer
NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to […]
Treating Advanced Prostate Cancer with Diet
Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer for early stage, localized, watch-and-wait cancer. […]
A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica
A USD 4.2 Billion Myovant/ Pfizer Deal Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as […]
Sharing experiences to level the healthcare playing field
Amanda Barrell speaks to Alfred Samuels on his experience of prostate cancer and diversifying clinical trials to include the Black, Asian and minority ethnic (BAME) […]
Can Soy Prevent and Treat Prostate Cancer?
As I discuss in my video The Role of Soy Foods in Prostate Cancer Prevention and Treatment, a compilation of 13 observational studies on soy […]
Fermented or Unfermented Soy?
As you can see at the start of my video Fermented or Unfermented Soy Foods for Prostate Cancer Prevention?, there is an enormous variation in […]
Food Combining for Prostate Cancer
What would happen if you secretly gave cancer patients four of the healthiest foods? In my video Pomegranate vs. Placebo for Prostate Cancer, I discussed […]
What Explains the Egg-Cancer Connection
The reason egg consumption is associated with elevated cancer risk may be the TMAO, considered the “smoking gun” of microbiome-disease interactions. “We are walking communities […]
AI algorithm for detecting prostate cancer shows more than 98% sensitivity, 97% specificity in study
Tel Aviv-based Ibex Medical Analytics published data on what it called the first algorithm to go beyond detection and into areas like tumor grading and […]
